63229_S123
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.480
- INTERFERON_ALPHA_RESPONSE+0.410
- INTERFERON_GAMMA_RESPONSE+0.390
- MYOGENESIS+0.360
- TNFA_SIGNALING_VIA_NFKB+0.310
- ANGIOGENESIS+0.300
- APICAL_JUNCTION+0.300
- NOTCH_SIGNALING+0.280
- P53_PATHWAY+0.280
- WNT_BETA_CATENIN_SIGNALING+0.270
Top 10 suppressed
- E2F_TARGETS-0.420
- MYC_TARGETS_V1-0.390
- G2M_CHECKPOINT-0.350
- MTORC1_SIGNALING-0.320
- PROTEIN_SECRETION-0.310
- CHOLESTEROL_HOMEOSTASIS-0.280
- OXIDATIVE_PHOSPHORYLATION-0.270
- SPERMATOGENESIS-0.270
- GLYCOLYSIS-0.210
- FATTY_ACID_METABOLISM-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R60 | — | — | 0.858 |
| 2 | BS_3Y0QXZQB | Neurofibroma | — | 0.857 |
| 3 | BS_TQ5QHR17 | Neurofibroma | — | 0.848 |
| 4 | MDT-AP-1128 | Med | Medulloblastoma | 0.845 |
| 5 | AUR-AER2-TTM3-A-1-1-R-A742-41 | — | D | 0.840 |
| 6 | BS_D4PJYHZ2 | Neurofibroma | — | 0.838 |
| 7 | TCGA-A2-A0YD-01A-11R-A109-07 | — | A | 0.831 |
| 8 | BS_5P3CZQV8 | Neurofibroma | — | 0.830 |
| 9 | SRR35579837 | — | D | 0.829 |
| 10 | BS_69V8P8A0 | Neurofibroma | — | 0.827 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.480 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.410 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.390 | Idelalisib | — uncovered |
| MYOGENESIS | 0.360 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.310 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.300 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.280 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.280 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.270 | Inavolisib | — uncovered |
| APOPTOSIS | 0.260 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.260 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.230 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.230 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.220 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.210 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.180 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.180 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.140 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.110 | Inavolisib | — uncovered |